Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Emergent BioSolutions Inc. Common Stock (NY: EBS )

8.150 +0.050 (+0.62%)
Official Closing Price Updated: 7:00 PM EST, Dec 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Emergent BioSolutions Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Emergent BioSolutions Successfully Refinances Debt & Further Strengthens Financial Profile
New favorable terms position Emergent for sustainable, long-term growth, as part of its multi-year plan to stabilize, turnaround and transform the company 
From Emergent BioSolutions
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Emergent BioSolutions Stock Storms Higher After The FDA Signs Off On Mpox Vaccine
Emergent BioSolutions stock jumped early Friday. 
Via Investor's Business Daily
Exposures Product Safety
Emergent BioSolutions Expands Ready to Rescue Initiative to Support Widespread Opioid Emergency Preparedness
From Emergent BioSolutions
Via GlobeNewswire
(EBS) - Analyzing Emergent BioSolutions's Short Interest
Via Benzinga
Mpox Vaccine: Emergent BioSolutions' Smallpox Vaccine Gets FDA Nod For Expanded Use For Individuals At High Risk Of Mpox Infection
The FDA has approved Emergent BioSolutions' supplemental Biologics License Application for ACAM2000 to include the prevention of mpox disease in high-risk individuals, with the approval based on human... 
Via Benzinga
Exposures Product Safety
Why MongoDB Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Emergent BioSolutions’ ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) Receives U.S. FDA Approval for Mpox Indication; Public Health Mpox Outbreak Continues Across Africa & Other Regions
From Emergent BioSolutions
Via GlobeNewswire
7 Analysts Assess Emergent BioSolutions: What You Need To Know
Via Benzinga
WHO Seeks $135M In Funding To Fight Mpox: Outbreak 'Can Be Controlled, And Can Be Stopped'
To fight the mpox outbreak in Africa, the World Health Organization calls for funding help for its six-month plan. 
Via Benzinga
Macy's Reports Weak Sales, Joins JD.com And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Emergent BioSolutions Finalizes Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Responds to Mpox Public Health Emergency as Cases Surge in Africa
From Emergent BioSolutions
Via GlobeNewswire
3 Promising Vaccine Stocks To Watch In The Event Of A Mpox Surge
Mpox rerun is making these stocks soar. But a non-vaccine approach could yield greater gains. 
Via Talk Markets
Why Emergent BioSolutions Stock Is Skyrocketing Today
Concerns about the mpox outbreak are causing Emergent BioSolutions' shares to jump. 
Via The Motley Fool
H&R Block Posts Upbeat Earnings, Joins Alibaba Group, CI&T And Other Big Stocks Moving Higher On Friday
Via Benzinga
Why Greenland Technologies Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Emergent Biosolutions, Bavarian Nordic, GeoVax And SIGA Technologies Shares Are Making Big Moves Thursday: What's Going On?
Several healthcare stocks associated with mpox are seeing increased attention Thursday after the World Health Organization declared a public health emergency in response to an mpox outbreak in Africa. 
Via Benzinga
Titan Machinery Reports Weak Preliminary Results, Joins Precigen, Gogoro And Other Big Stocks Moving Lower In Thursday Pre-Market Session
Via Benzinga
WHO Declares Mpox Public Health Emergency: 'Coordinated International Response Essential' To Halt Outbreak
A public health emergency for mpox in Africa saw vaccine stocks jump Wednesday. A look at the stocks and what's next for fighting the virus. 
Via Benzinga
Vaccine Maker Emergent BioSolutions Expects Deeper Losses In 2024, Stock Sinks
Emergent BioSolutions reported Q2 2024 sales of $254.7 million, beating estimates but showing a 25% decline year-over-year. Despite a significant adjusted EPS loss and mixed performance across product... 
Via Benzinga
Airbnb Reports Weak Earnings, Joins Cryoport, Tripadvisor, Lyft And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Pre-market stock movers are a hot topic on Wednesday and we have all of the latest news traders need to know about them this morning! 
Via InvestorPlace
Why Fortinet Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Emergent BioSolutions (EBS) Q2 2024 Earnings Call Transcript
EBS earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Emergent BioSolutions Reports Second Quarter 2024 Financial Results
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Expands NARCAN® Nasal Spray Distribution Capabilities to Enhance Customer Delivery Experience Across the Country
From Emergent BioSolutions
Via GlobeNewswire
8 Best-Performing Small Caps In July: Find Out Which Stock Jumped 803%
Macro environment favors large-caps, but July saw impressive gains for small-caps, with Serve Robotics leading at 803% and Q32 Bio at 101%. 
Via Benzinga
Emergent BioSolutions Completes Sale of RSDL® (Reactive Skin Decontamination Lotion) Kit to SERB Pharmaceuticals for $75 Million
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Launches Opioid Emergency Preparedness ‘Lay, Spray, Stay’ Public Education Campaign Starring Pro Football Hall of Famer Emmitt Smith
From Emergent BioSolutions
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.